Aimmune Therapeutics Inc AIMT:NASDAQ

Last Price$20.42Cboe Real-Time Last Sale as of 12:50PM ET 6/17/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+0.42(2.10%)
Bid (Size)$20.40 (100)
Ask (Size)$20.46 (67)
Day Low / High$20.21 - 20.54
Volume135.6 K
 

View Biotechnology IndustryPeer Comparison as of 06/17/2019

 

Aimmune Therapeutics Inc ( NASDAQ )

Price: $20.42
Change: +0.42 (2.10%)
Volume: 135.6 K
12:50PM ET 6/17/2019
 
 

Coherus BioSciences Inc ( NASDAQ )

Price: $19.06
Change: +0.41 (2.20%)
Volume: 208.2 K
12:52PM ET 6/17/2019
 
 

Veracyte Inc ( NASDAQ )

Price: $28.47
Change: +0.90 (3.26%)
Volume: 254.6 K
12:52PM ET 6/17/2019
 
 

Momenta Pharmaceuticals Inc ( NASDAQ )

Price: $12.41
Change: +0.43 (3.59%)
Volume: 102.2 K
12:50PM ET 6/17/2019
 
 

Esperion Therapeutics Inc ( NASDAQ )

Price: $50.39
Change: +1.22 (2.48%)
Volume: 150.0 K
12:49PM ET 6/17/2019
 

Read more news Recent News

Aimmune Therapeutics to Discuss AR101's Cost-Effectiveness for Peanut Allergy Treatment at ICER Meeting
9:30AM ET 6/11/2019 MT Newswires

Shares of Aimmune Therapeutics (AIMT) were down 1.34% pre-market as the company announced plans to discuss the effectiveness and value of treatments for...

Aimmune Therapeutics Presents New Data From Follow-On Study of AR101 for Peanut Allergy
8:12AM ET 6/04/2019 MT Newswires

Aimmune Therapeutics (AIMT) said Tuesday that new data from a follow-on study of its peanut allergy drug AR101 showed that extending daily therapy with...

Analyst Actions: Credit Suisse Cuts Aimmune Therapeutics PT to $30 from $36, Assumes Coverage at Outperform on Peanut Allergy Drug - Stock Up 3%
2:04PM ET 5/21/2019 MT Newswires

Credit Suisse has cut its price target on Aimmune Therapeutics (AIMT) to $30 from $36 while assuming its outperform rating, betting on its current...

Aimmune Therapeutics' Peanut Allergy Drug Set for FDA Review Meeting Sept. 13
2:40PM ET 5/16/2019 MT Newswires

Aimmune Therapeutics (AIMT) said the US Food and Drug Administration will review the application for its peanut allergy drug at a Sept. 13 meeting. The...

Company Profile

Business DescriptionAimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA. View company web site for more details
Address8000 Marina Boulevard
Brisbane, California 94005-1884
Phone+1.650.614.5220
Number of Employees215
Recent SEC Filing05/30/20198-K
President, Chief Executive Officer & DirectorJayson Donald Alexander Dallas
Chief Financial OfficerEric H. Bjerkholt
Chief Medical OfficerDaniel C. Adelman
Senior VP-Corporate Development & StrategyMary M. Rozenman

Company Highlights

Price Open$20.13
Previous Close$20.00
52 Week Range$19.25 - 36.12
Market Capitalization$1.3 B
Shares Outstanding62.5 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement08/14/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.62
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit MarginN/A
Return on Equity-79.07%

Analyst Ratings as of 06/07/2019

Buy
7
Overweight
1
Hold
2
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset